Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"image","alt":"Quantum BioPharma","displaySize":"","headline":null,"caption":"Quantum BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qja15kgwsxmPJl2bRABEww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3","width":300,"height":87},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/qja15kgwsxmPJl2bRABEww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3","width":300,"height":87}},"lazy":false},{"type":"text","content":"Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis","length":124,"tagName":"p"},{"type":"text","content":"TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression and treatment response are measured.","length":777,"tagName":"p"},{"type":"text","content":"At the center of this effort is the PET tracer [¹⁸F]3F4AP, developed by Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School. In prior preclinical and clinical studies, [¹⁸F]3F4AP demonstrated high sensitivity for detecting demyelinated lesions along with favorable pharmacokinetics, positioning it as a promising biomarker for monitoring myelin damage and repair.","length":433,"tagName":"p"},{"type":"text","content":"Importantly, early data from the ongoing study reinforce this potential. The first cohort of participants has been successfully ...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B